Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Vir Biotechnology, Inc is a biotechnology business based in the US. Vir Biotechnology shares (VIR) are listed on the NASDAQ and all prices are listed in US Dollars. Vir Biotechnology employs 253 staff and has a trailing 12-month revenue of around USD$75.1 million.
|Latest market close||USD$35.91|
|52-week range||USD$11.6504 - USD$75|
|50-day moving average||USD$40.3849|
|200-day moving average||USD$38.3836|
|Wall St. target price||USD$51.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-5.76|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-24)||11.25%|
|1 month (2020-09-01)||5.96%|
|3 months (2020-07-01)||-9.32%|
|6 months (2020-04-01)||20.62%|
|1 year (2019-09-27)||N/A|
|2 years (2018-09-27)||N/A|
|3 years (2017-09-27)||N/A|
|5 years (2015-09-27)||N/A|
|Revenue TTM||USD$75.1 million|
|Gross profit TTM||USD$-134,981,000|
|Return on assets TTM||-22.96%|
|Return on equity TTM||-45.69%|
|Market capitalisation||USD$4.1 billion|
TTM: trailing 12 months
There are currently 3.4 million Vir Biotechnology shares held short by investors – that's known as Vir Biotechnology's "short interest". This figure is 13.6% up from 3.0 million last month.
There are a few different ways that this level of interest in shorting Vir Biotechnology shares can be evaluated.
Vir Biotechnology's "short interest ratio" (SIR) is the quantity of Vir Biotechnology shares currently shorted divided by the average quantity of Vir Biotechnology shares traded daily (recently around 828975.12077295). Vir Biotechnology's SIR currently stands at 4.14. In other words for every 100,000 Vir Biotechnology shares traded daily on the market, roughly 4140 shares are currently held short.
However Vir Biotechnology's short interest can also be evaluated against the total number of Vir Biotechnology shares, or, against the total number of tradable Vir Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vir Biotechnology's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Vir Biotechnology shares in existence, roughly 30 shares are currently held short) or 0.0536% of the tradable shares (for every 100,000 tradable Vir Biotechnology shares, roughly 54 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vir Biotechnology.
Find out more about how you can short Vir Biotechnology stock.
We're not expecting Vir Biotechnology to pay a dividend over the next 12 months.
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.